Luxturna's EU Approval Highlights Gene Therapy Pricing Challenges
Executive Summary
Novartis/Spark Therapeutics’ transformative gene therapy Luxturna has just been approved in the EU. Like other gene therapies, it comes with a heavy price tag. So how will Novartis convince payers to pay, and how will payers cope with expensive, game changing therapies in the future?
You may also be interested in...
Novartis Prepares for UK Luxturna Rollout After Rapid NICE OK
Novartis/Spark’s gene therapy Luxturna has been OKd for NHS use by NICE in record time thanks to early engagement and close collaboration between the two parties.
Luxturna Secures English Reimbursement In Record Time
Novartis/Spark’s Luxturna has been authorized by NICE for use in England after the company agreed a discount on the list price that made the gene therapy cost effective for the national health service. The recommendation was made in record time thanks to good collaboration between the two parties.
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.